Article and Video CATEGORIES

Cancer Journey

Search By

2020 PEA Program - Medhavi Gupta MD, Breast Cancer Series Antibody-Drug Conjugate Treatment Options
2020 PEA Program Breast Cancer Series - Gupta - Antibody-Drug Conjugate Treatment Options
Author
Medhavi Gupta, MD
Image
Dr. Medhavi Gupta, one of the participants in this past year's GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer.

For this series, Dr. Gupta discusses Metastatic Triple-Negative Breast Cancer with Dr. Aditya Bardai.

Dr. Bardai is Assistant Professor of Medicine at Harvard Medical School and Attending Physician in Medical Oncology at Massachusetts General Hospital.

 

In this video, Drs. Gupta and Bardai discuss Antibody-Drug Conjugate Treatment Options

#breastcancer #Metastases #triplenegative #cancerGRACE #genentech #lilly

To join the conversation, visit https://cancergrace.org/forum.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on